Compare ANIK & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIK | MSLE |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 186.9M |
| IPO Year | 1996 | 2007 |
| Metric | ANIK | MSLE |
|---|---|---|
| Price | $19.96 | $6.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $23.00 | ★ $24.17 |
| AVG Volume (30 Days) | ★ 83.9K | 63.5K |
| Earning Date | 11-04-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.01 | $5.44 |
| 52 Week High | $22.88 | $13.39 |
| Indicator | ANIK | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 25.29 |
| Support Level | $14.00 | $5.52 |
| Resistance Level | $22.70 | $10.58 |
| Average True Range (ATR) | 0.83 | 0.59 |
| MACD | 0.07 | -0.14 |
| Stochastic Oscillator | 66.43 | 0.00 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.